Annual Cash & Cash Equivalents
$179.91 M
-$145.18 M-44.66%
December 31, 2023
Summary
- As of February 8, 2025, PACB annual cash & cash equivalents is $179.91 million, with the most recent change of -$145.18 million (-44.66%) on December 31, 2023.
- During the last 3 years, PACB annual cash & cash equivalents has risen by +$98.30 million (+120.45%).
- PACB annual cash & cash equivalents is now -60.95% below its all-time high of $460.73 million, reached on December 31, 2021.
Performance
PACB Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$77.98 M
-$21.54 M-21.65%
September 30, 2024
Summary
- As of February 8, 2025, PACB quarterly cash and cash equivalents is $77.98 million, with the most recent change of -$21.54 million (-21.65%) on September 30, 2024.
- Over the past year, PACB quarterly cash and cash equivalents has dropped by -$21.54 million (-21.65%).
- PACB quarterly cash and cash equivalents is now -91.64% below its all-time high of $932.40 million, reached on March 31, 2021.
Performance
PACB Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
PACB Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -44.7% | -21.6% |
| 3 y3 years | +120.5% | -81.7% |
| 5 y5 years | +854.7% | +135.7% |
PACB Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -61.0% | at low | -83.1% | +1.7% |
| 5 y | 5-year | -61.0% | +507.3% | -91.6% | +163.2% |
| alltime | all time | -61.0% | +989.9% | -91.6% | +372.4% |
Pacific Biosciences Of California Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $77.98 M(-21.6%) |
| Jun 2024 | - | $99.53 M(+29.9%) |
| Mar 2024 | - | $76.65 M(-57.4%) |
| Dec 2023 | $179.91 M(-44.7%) | $179.91 M(-53.3%) |
| Sep 2023 | - | $385.65 M(+84.3%) |
| Jun 2023 | - | $209.29 M(-40.9%) |
| Mar 2023 | - | $353.83 M(+8.8%) |
| Dec 2022 | $325.09 M(-29.4%) | $325.09 M(+6.8%) |
| Sep 2022 | - | $304.43 M(-1.9%) |
| Jun 2022 | - | $310.44 M(-27.6%) |
| Mar 2022 | - | $428.57 M(-7.0%) |
| Dec 2021 | $460.73 M(+464.5%) | $460.73 M(+8.3%) |
| Sep 2021 | - | $425.39 M(-7.5%) |
| Jun 2021 | - | $459.79 M(-50.7%) |
| Mar 2021 | - | $932.40 M(+1042.5%) |
| Dec 2020 | $81.61 M(+175.5%) | $81.61 M(+18.2%) |
| Sep 2020 | - | $69.03 M(+59.3%) |
| Jun 2020 | - | $43.34 M(-37.1%) |
| Mar 2020 | - | $68.86 M(+132.4%) |
| Dec 2019 | $29.63 M(+57.2%) | $29.63 M(-10.4%) |
| Sep 2019 | - | $33.08 M(+9.0%) |
| Jun 2019 | - | $30.36 M(-20.5%) |
| Mar 2019 | - | $38.20 M(+102.7%) |
| Dec 2018 | $18.84 M(+14.2%) | $18.84 M(-50.5%) |
| Sep 2018 | - | $38.06 M(+65.1%) |
| Jun 2018 | - | $23.06 M(-9.4%) |
| Mar 2018 | - | $25.46 M(+54.2%) |
| Dec 2017 | $16.51 M | $16.51 M(-36.3%) |
| Sep 2017 | - | $25.93 M(-28.9%) |
| Jun 2017 | - | $36.48 M(+25.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2017 | - | $28.98 M(+72.9%) |
| Dec 2016 | $16.77 M(-50.1%) | $16.77 M(-26.4%) |
| Sep 2016 | - | $22.79 M(-8.0%) |
| Jun 2016 | - | $24.78 M(+23.4%) |
| Mar 2016 | - | $20.08 M(-40.3%) |
| Dec 2015 | $33.63 M(-7.7%) | $33.63 M(+23.6%) |
| Sep 2015 | - | $27.21 M(+4.9%) |
| Jun 2015 | - | $25.93 M(-14.3%) |
| Mar 2015 | - | $30.27 M(-16.9%) |
| Dec 2014 | $36.45 M(+38.3%) | $36.45 M(+2.9%) |
| Sep 2014 | - | $35.41 M(+25.6%) |
| Jun 2014 | - | $28.20 M(-31.7%) |
| Mar 2014 | - | $41.26 M(+56.5%) |
| Dec 2013 | $26.36 M(-43.4%) | $26.36 M(-59.3%) |
| Sep 2013 | - | $64.77 M(+58.6%) |
| Jun 2013 | - | $40.83 M(-23.0%) |
| Mar 2013 | - | $53.04 M(+14.0%) |
| Dec 2012 | $46.54 M(-20.9%) | $46.54 M(+42.9%) |
| Sep 2012 | - | $32.56 M(-3.2%) |
| Jun 2012 | - | $33.62 M(-40.2%) |
| Mar 2012 | - | $56.26 M(-4.4%) |
| Dec 2011 | $58.87 M(-60.1%) | $58.87 M(+2.2%) |
| Sep 2011 | - | $57.58 M(+5.6%) |
| Jun 2011 | - | $54.51 M(-35.6%) |
| Mar 2011 | - | $84.61 M(-42.7%) |
| Dec 2010 | $147.65 M(+65.5%) | $147.65 M(+135.4%) |
| Sep 2010 | - | $62.72 M(-30.4%) |
| Jun 2010 | - | $90.14 M(+1.0%) |
| Dec 2009 | $89.23 M(+13.7%) | $89.23 M |
| Dec 2008 | $78.46 M | - |
FAQ
- What is Pacific Biosciences of California annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Pacific Biosciences of California?
- What is Pacific Biosciences of California annual cash & cash equivalents year-on-year change?
- What is Pacific Biosciences of California quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Pacific Biosciences of California?
- What is Pacific Biosciences of California quarterly cash and cash equivalents year-on-year change?
What is Pacific Biosciences of California annual cash & cash equivalents?
The current annual cash & cash equivalents of PACB is $179.91 M
What is the all time high annual cash & cash equivalents for Pacific Biosciences of California?
Pacific Biosciences of California all-time high annual cash & cash equivalents is $460.73 M
What is Pacific Biosciences of California annual cash & cash equivalents year-on-year change?
Over the past year, PACB annual cash & cash equivalents has changed by -$145.18 M (-44.66%)
What is Pacific Biosciences of California quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of PACB is $77.98 M
What is the all time high quarterly cash and cash equivalents for Pacific Biosciences of California?
Pacific Biosciences of California all-time high quarterly cash and cash equivalents is $932.40 M
What is Pacific Biosciences of California quarterly cash and cash equivalents year-on-year change?
Over the past year, PACB quarterly cash and cash equivalents has changed by -$21.54 M (-21.65%)